Page 7 of 10: studies 121 to 140 of 193, newest first. Back to the anxiety overview
Journal of Sleep Medicine April 29, 2021 Sooyeon Suh 1 citation
(rapid eye movement, REM) , . ' ' ,
Electronic Journal of General Medicine April 27, 2021 Hisham Alshaikhli, Redhwan Ahmed Al-Naggar, Gwen Erlam 14 citations
Introduction: Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. \nObjective: The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. \nMethod: A qualitative study was conducted interviewing ten participants currently taking...
Trials April 23, 2021 Robin J Murphy, Rachael Sumner, William Evans et al. 23 citations
BACKGROUND: Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as "microdosing", has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional domains. Rigorously controlled studies to date, however, have been limited in scope and have failed to produce results comparable to those reported...
British Medical Bulletin April 21, 2021 Dexing Zhang, Kam-Pui Lee, E Mák et al. 638 citations
INTRODUCTION: This is an overall review on mindfulness-based interventions (MBIs). SOURCES OF DATA: We identified studies in PubMed, EMBASE, CINAHL, PsycINFO, AMED, Web of Science and Google Scholar using keywords including 'mindfulness', 'meditation', and 'review', 'meta-analysis' or their variations. AREAS OF AGREEMENT: MBIs are effective for improving many biopsychosocial conditions,...
Psychiatry Research April 20, 2021 Xiaoyu Liu, Peng Yi, Lijun Ma et al.
Various psychiatric disorders are treated with mindfulness-based interventions (MBIs), although the efficacy of MBIs in patients with social anxiety disorder (SAD) is unclear. In this meta-analysis, we investigated the efficacy of MBIs on SAD symptoms. Systematic searches were performed in various databases, and 11 eligible randomized controlled trials (RCTs) and 5 single-arm trials were...
International Journal of Cognitive Therapy April 20, 2021 Emilee E. Burgess, Steven Selchen, Benjamin D. Diplock et al.
Mindfulness-based interventions (MBIs) have emerged as clinically effective interventions for anxiety and depression although there are significant barriers to their access in the general population. The present study examined the effectiveness of a 5-week abbreviated mindfulness-based cognitive therapy (MBCT) intervention for a physician-referred, treatment-seeking, community sample (N = 54)...
Bio-protocol April 20, 2021 M Rezaul Karim
Muscimol is a psychoactive isoxazole derived from the mushroom Amanita muscaria. As a potent GABAA receptor agonist, muscimol suppresses the activity of the central nervous system, reduces anxiety and induces sleep. We investigated the effects of muscimol on Drosophila behavior. Drosophila behavioral assays are powerful tools that are used to assess neural functions by focusing on specific...
Psychotherapy and Psychosomatics April 19, 2021 Natalie L. Marchant, Thorsten Barnhofer, Roxane Coueron et al.
Introduction: Older adults experiencing subjective cognitive decline (SCD) have a heightened risk of developing dementia and frequently experience subclinical anxiety, which is itself associated with dementia risk. Objective: To understand whether subclinical anxiety symptoms in SCD can be reduced through behavioral interventions. Methods: SCD-Well is a randomized controlled trial designed to...
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature April 15, 2021 Dave Nichols
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a...
April 13, 2021 Marco Schlosser, Thorsten Barnhofer, Florence Requier et al. 2 citations
Objectives: Deepening our understanding of the mechanisms by which meditation practices impact well-being and human flourishing is essential for advancing the science of meditation. The phenomenologically grounded classification system introduced by Dahl, Lutz, and Davidson (2015) distinguishes attentional, constructive, and deconstructive forms of meditation based on the psychological...
Journal of Clinical Psychopharmacology April 13, 2021 Juliana Mendes Rocha, Giordano Novak Rossi, Flávia de Lima Osório et al. 46 citations
Abstract Background The recognition of emotions in facial expressions (REFE) is a core aspect of social cognition. Previous studies with the serotonergic hallucinogens lysergic acid diethylamide and psilocybin showed that these drugs reduced the recognition of negative (fear) faces in healthy volunteers. This trial assessed the acute and prolonged effects of a single dose of ayahuasca on the...
Journal of Palliative Medicine April 5, 2021 Jordan A Carver, Katharine L. Cheung
Kidney failure, or end-stage kidney disease (ESKD), is a life-altering condition, with a one-year mortality rate of 20%–25%, 1 and the incidence is expected to rise 11%–18% by 2030, compared with 2015 levels. 2 Patients with kidney failure experience a high burden of symptoms that are often unaddressed during their dialysis treatments. The COVID-19 pandemic
April 2, 2021 Katharina Dworatzyk, Tallulah Jansen, Timo Torsten Schmidt 3 citations preprint
Several measures have been designed to assess subjective experiences induced by psychedelic substances and other mind-altering drugs or non-pharmacological methods. Recently, two self-report questionnaires have been introduced to measure acute adverse effects following psilocybin ingestion and the phenomenon of ego-dissolution associated with psychedelic use, respectively. The 26-item...
The Journal of Nervous and Mental Disease April 1, 2021 Siamak Khodarahimi, Fazlolah Mirderikvand, Kourosh Amraei
This study aimed to examine the effect of an Affective and Sensory Psychotherapy Protocol (ASPP) on dream awareness in adults with generalized anxiety disorder (GAD). For this purpose, 60 self-referred male and female adults were studied within a randomized clinical trial. The Generalized Anxiety Disorder 7-Item Scale and the Mannheim Dream Questionnaire were used at baseline, posttreatment,...
Psychiatric News April 1, 2021 Charles S. Grob
After decades of quiescence, psychedelics are back and making quite a ruckus. In the 1950s and 1960s, a flurry of cutting-edge psychedelic research engendered real enthusiasm among clinicians, suggesting potential treatment efficacy for a range of serious refractory disorders. But a cultural and political backlash led to the imposition of draconian laws, effectively sidelining psychedelic...
European Psychiatry April 1, 2021 R. Pinilla, Carmen Rocamora Rodriguez, D. Batet-Sanchez et al. 3 citations
Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinical existing evidence. Methods A literature review was carried out in the databases pubmed, clinical key and texts of scientific dissemination. Results There´s scientific literature about the potential therapeutic use of ayahuasca in dependencies,...
European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...
European Psychiatry April 1, 2021 S. Torres 2 citations
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....
European Psychiatry April 1, 2021 A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira et al. 1 citation
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects on mood and cognition could...
March 30, 2021 Matthew J. Hirshberg, Corrina Frye, Cortland J. Dahl et al. 5 citations preprint
While the extraordinary pressures of the COVID-19 pandemic on student mental health have received considerable attention, less attention has been placed on the well-being of educators. School system employees play a vital role in society, and teacher levels of well-being are associated with the educational outcomes of young people. We extend extant research on the prevalence and correlates of...